Lanicemine dihydrochloride (AZD-6765 dihydrochloride) is a low-capture NMDA channel blocker with antidepressant activity and can be used to study neurological diseases.

The levels of the GluA1 subunit of AMPA receptors, synapsin I, BDNF, and CREB after treatment of mice with either hyperforin or Lanicemine dihydrochloride or a combination of both drugs. This treatment strategy did not significantly alter p-CREB/CREB levels but elevated BDNF in the frontal cortex (1 h after hyperforin and 1.5 h after Lanicemine dihydrochloride administration). A single dose of either hyperforin or Lanicemine dihydrochloride did not alter the expression of synapsin I and GluA1. In contrast, the combined administration of hyperforin and Lanicemine dihydrochloride increased the levels of both proteins. After 72 h, a combination of hyperforin and Lanicemine dihydrochloride did not alter p-CREB/CREB levels; however, Lanicemine dihydrochloride and hyperforin + Lanicemine dihydrochloride significantly increased the levels of BDNF in the test animals compared to controls. The levels of other proteins (synapsin I, GluA1) remained unchanged 72 h after treatment. [1]